CD138 (Syndecan-1) Monoclonal Antibody (DL-101), FITC, eBioscience™, Invitrogen™

Description

• Description: The DL-101 monoclonal antibody reacts with human CD138, also known as syndecan-1
• CD138 is a transmembrane protein containing chondroitin sulfate and heparin sulfate moieties responsible for binding to the extracellular matrix components
• CD138 is not expressed by mature B cells but is present on pre-B cells and the finally differentiated plasma cells
• Applications Reported: DL-101 has been reported for use in flow cytometric analysis
• Applications Tested: This DL-101 antibody has been pre-titrated and tested by flow cytometric analysis of the U266 cell line
• This can be used at 5 μL (1 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD138 (syndecan 1) is a transmembrane proteoglycan that can bind a variety of cytokines and modulate their activity, as well as the activity of extracellular matrix components and influence many developmental processes
• CD138 is expressed mainly in differentiating keratinocytes and is transiently upregulated in all layers of the epidermis upon tissue injury
• It is also highly expressed on plasma cells and can be detected even on fibroblasts, vascular smooth muscle cells and endothelial cells
• Up-regulation and down-regulation of CD138 on the cell surface often correlates with the gain of cancerous characteristics
• Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis.